Elevian, Inc. is focused on developing innovative therapies aimed at promoting recovery and regeneration, particularly in the context of stroke, which currently lacks effective treatments for recovery in the days following the event. Their lead therapeutic candidate, a recombinant protein known as rGDF11, has shown promise in preclinical studies for enhancing motor function recovery after both ischemic and hemorrhagic strokes. rGDF11 works by promoting neovascularization, stimulating neurogenesis, and reducing inflammation, thereby facilitating recovery in various animal models. This protein's regenerative capabilities extend beyond stroke, indicating potential applications in treating a range of aging-associated diseases, including cardiovascular, neurological, and metabolic disorders.

The company is advancing its research on rGDF11 and other modulators of the GDF11 pathway, with a particular emphasis on addressing the significant unmet medical need in stroke treatment. Elevian's approach is distinct from existing therapies, which primarily focus on neuroprotection rather than recovery. Their findings suggest that rGDF11 can improve motor function and promote recovery even when treatment is initiated days after a stroke. Additionally, Elevian has established a robust manufacturing process for rGDF11, ensuring the production of high-quality, active protein for clinical studies. The company holds a growing portfolio of patents related to the therapeutic use of GDF11, underscoring its commitment to advancing this promising area of regenerative medicine.

United States

At Elevian, we are developing new medicines that promote recovery and regeneration. Our lead program is a recombinant protein for the treatment of stroke in the days following the event, for which there are currently no viable treatments. By promoting regeneration, Elevian’s medicines have the potential to treat and prevent many aging-associated diseases. 

Elevian, Inc.

Company Details